HOWL News and Press, Werewolf Therapeutics Inc. From 01/08/24

-  Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE TM programs anticipated in 2024 - -  WTX-124: updated interim monotherapy dose-escalation data and initial combination dose escalation data from Phas...

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics enginee...

2023-12-28 19:09:27 ET Summary HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses seen. HOWL has room to impress further, with a...

2023-12-08 09:30:00 ET December 8, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Life Sciences, Fintech and Defense. Today's stocks have been added to our lists of fre...

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body...

2023-11-14 17:02:26 ET Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q3 GAAP EPS of -$0.23. Revenue of $5.9M (+18.7% Y/Y). As of September 30, 2023, cash and cash equivalents were $130.1 million. Expects that its existing cash and cash equivalents will be s...

–  Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity – –  Safety data indicate WTX-124 is generally wel...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Werewolf Therapeutics Inc. (HOWL) is expected to report $-0.27 for Q3 2023

2023-11-07 08:36:07 ET Losers: Ventyx Biosciences ( VTYX ) -76% announces results from the phase 2 trial of VTX958 in patients with moderate to severe plaque Psoriasis and provides corporate update. Alto Ingredients ( ALTO ) -50% reports third quarter 2023 re...